Articles On Zelda Therapeutics (ASX:ZLD)

In what may be a catalyst for ASX cannabis shares, a private company today gained approval to grow medicinal cannabis in Western Australia. As reported by the ABC, the private medicinal cannabis company Elite Cannabinoids has received appr...

Australia has one of the highest rates of household pet ownership in the world. The RSPCA estimates 61 per cent of Australian households own pets and all up there are over 29 million pets across the country. The most common domesticated an...

There is a sector in Australia that’s about to grow its revenue by 478% in the current financial year, according to one analyst. Consumer research firm IBISWorld revealed Tuesday that the medical cannabis manufacturing industry is currentl...

Investors in ASX cannabis shares have had a bumpy ride in 2020. Share prices were impacted by global oversupply issues in late 2019 then plunged in the March 2020 market downturn. But the Australian medical marijuana industry is building...

The share price of medical cannabis company Zelira Therapeutics Ltd (ASX:ZLD) has rocketed today thanks to a distribution agreement in the Washington DC area, US. At time of writing the ZLD share price is up 36.36% or 3.6 cents to trade at...

The Zelira Therapeutics Ltd (ASX: ZLD) share price is breaking new records today. This comes after the company announced a new licencing agreement with Alternative Solutions LLC. Alternative Solutions is a licenced grower, manufacturer and...

Shares in Zelira Therapeutics (ASX:ZLD) have risen more than 30 per cent to a nearly two-year high in early trade ... Read More The post Zelira shares soar after expanding US medical pot distribution appeared first on Stockhead.

Summary During September quarter, Zelira Therapeutics achieved significant milestones marking its successful transition to the ‘Launch, Learn and Develop’ model. Key developments include the launch of Zenivol™ in Australia and HOPE™ in...

Summary Zelira Therapeutics forays into the US oral care market by launching CBD toothpaste in partnership with US-based SprinJene®. The new CBD toothpaste will be Zelira’s first Over-the-Counter formulation. Further, the discussions...

Summary Leading biopharmaceutical company Zelira Therapeutics signed an agreement with Emyria Ltd for Autism Observational Trial of HOPE™ products. The Trial will collect efficacy and safety data from patients diagnosed with ASD and ha...

Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator’s endorsement of the weed as an effective therapy that should be more freely available to the a...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes for the week It’s been...

Listed cannabis company Zelira Therapeutics (ASX: ZLD) has today formed a new Oral Care products subsidiary, tasked with selling a hemp-derived cannabinoid-based toothpaste. The company plans on launching the toothpaste product in the USA...

Listed cannabis company Zelira Therapeutics (ASX: ZLD) has today formed a new Oral Care products subsidiary, tasked with selling a hemp-derived cannabinoid-based toothpaste. The company plans on launching the toothpaste product in the USA...

08 Sep 2020 - Global therapeutic medicinal cannabis company, Zelira Therapeutics (ASX:ZLD) has expanded into the dental health market by launching a scientifically formulated, hemp…

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With repor...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Dr Richard Hopkins, Managing Director of Zeli...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The pundit...

Zelira (ASX: ZLD) has partnered with US-based Cardiovascular Solutions of Central Mississippi (CVSCM) to develop and commercialise CBD and hemp products to target symptoms associated with Peripheral Arterial Disease (PAD) and Diabetic Neuro...

Medical cannabis company Zelira Therapeutics (ASX: ZLD) has committed to a binding five-year agreement with US-based company Cardiovascular Solutions of Central Mississippi (CVSCM) to develop and commercialise products to treat symptoms ass...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The market...

Zelira Therapeutics (ASX:ZLD) has completed another medicinal cannabis trial and passed with flying colours. This time it was a Phase 1 dose escalation study assessing the safety of its cannabis formulation in chronic pain patients using op...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week As markets...

Since the start of March, six clinical trials involving cannabis treatments around the world have been halted or cancelled altogether due to COVID19 pandemic but 179 are still recruiting, according to the US registry ClinicalTrials.com. Mor...

Australian medicinal cannabis company Zelira Therapeutics (ASX:ZLD) has announced a commercial supply agreement with Tasmanian Alkaloids (TasAlk) to manufacture the Insomnia and HOPE medicinal cannabis formulations.

Perth-based medicinal cannabis company Zelira Therapeutics (ASX:ZLD) has announced it has demonstrated its formulation ZLT-101 works for people suffering insomnia. 

Zelira Therapeutics (ASX: ZLD) has announced its Phase 1b/2a medicinal cannabis trial to treat insomnia has met both its primary and secondary endpoints. The company today confirmed it has received the final clinical report for the trial, w...

In proof that biotechs will deliver market returns even during a pandemic, two companies this morning have issued clinical trial results and watched their share prices rocket. Pot stock Zelira Therapeutics (ASX:ZLD) has received the full re...

Zelira Therapeutics (ASX:ZLD) chief Dr Richard Hopkins confirms what your columnist suspected was a self-serving myth perpetuated by overzealous users of the intoxicating herb: no one has ever been recorded as overdosing on cannabis over mi...

Medicinal cannabis company Zelira Therapeutics (ASX:ZLD) says its Phase 1 Dose Escalation Trial in patients on long-term opioid treatment is now fully enrolled.

Little Green Pharma (ASX:LGP) announced a new export partner — and it happens to be the only company covering the entire medicinal cannabis production chain. Berlin-based Deutsche Medizinalcannabis (Demecan) will import and sell LGP’s Class...

Two years ago Zelira (ASX:ZLD) — then Zelda — was set to invade the German market, planning to storm the walls with unregistered marijuana products that had a little bit of clinical data behind them, data which would be the reason for a big...

Another ASX small cap has won the blessing of the Food and Drug Administration (FDA) for its products enter the US market. This morning it was Compumedics (ASX:CMP). Its signature product, the Orion LifeSpan Magnetoencephalography single De...

Medicinal cannabis company Zelira Therapeutics (ASX:ZLD) has completed a placement of 91,770,000 fully-paid ordinary shares at a share price of $0.05 to Australian and International investors.

Therapeutic medicinal cannabis company, Zelira Therapeutics (ZLD) has successfully completed a $4.5 million placement The placement was fully supported by existing and new shareholders Funds will be used to launch new products into the glo...

Elixinol Global (ASX:EXL) is bleeding money and is holding a fire sale of its global hemp and medical cannabis assets. Today the company said it was selling its Hemp Foods Australia subsidiary to a Chinese buyer for just $500,000. It is kil...

Quarterly reports for biotechs usually only tell investors how much cash they have left — and how much time they have until the next cap raise. But December quarterlies from late Friday and today include several companies that are making mo...

Zelira Therapeutics (ASX:ZLD) has announced a collaboration with the US-based Parkinson’s Foundation to gather insights from people with PD about their understanding of and use of medical cannabis and hemp-derived therapies.

Only one prescription for medical marijuana has been issued by a doctor in the Northern Territory, according to Minister for Health Natasha Fyles. In a submission to the Senate inquiry into barriers to patient access to marijuana, Fyles sai...

For an industry that’s projected to reach $US20 billion ($29 billion) by 2024 in the US, the cannabidiol (CBD) market there is very much the wild west. A study from researcher Leafreport comparing 3500 products for the sale in the US from 5...

There are many reasons why a company might change its name, from being taken over to hiding a shady past. This year 114 companies have changed their name. Family cyber security provider Wangle Technologies became the much more fitting Famil...

Marijuana is the hottest herb on the planet right now, but while investing in medical cannabis stocks could make you a fortune, it could also risk the house. After a flurry of activity on the ASX in 2017 as the sector kicked off following l...

An Initial Public Offering (IPO) is a process in which a private company offers its shares to the public through stock issuance. An IPO is the best way for a company to raise a substantial amount of capital to expand its operations. The fun...

Zelira Therapeutics Limited (ASX: ZLD) has announced that last patient has completed dosing in its pioneering medicinal cannabis trial cannabis for insomnia. The company expects to report half-year results by February 2020. It is said that...

New Zealand’s medicines regulator has recommended the country fall in line with Australia’s new codeine restrictions, and pharmaceutical companies are backing the decision. Yesterday, Medsafe recommended that all medications containing code...

05 Dec 2019 - Zelda Therapeutics (ASX:ZLD) has confirmed the company has changed its name to Zelira Therapeutics.

Pot stock THC Global (ASX:THC) is in business at Southport, the largest medicinal cannabis production hub in the southern hemisphere. The company announced the release of its completed Canndeo line of cannabis medicines, cultivated using ma...

The THC Global Group Ltd (ASX: THC) share price has returned from its trading halt and surged higher. At the time of writing the cannabis company’s shares are up 11% to 41 cents. Why were THC Global’s shares in a trading halt? THC Global r...

Zelira Therapeutics, formerly known as Zelda Therapeutics (ASX:ZLD), has announced the completion of the 100 per cent acquisition of Ilera Therapeutics.

Zelda Therapeutics’ (ASX: ZLD) medicinal cannabis products will be distributed across Australasia and the United Kingdom under a new agreement with Health House Holdings Ltd. The agreement follows Zelda’s intent to launch its HOPE products...